Client work
SOL Global portfolio company Heavenly Rx closes on its $30.06 million investment in Blühen Botanicals
On May 23, 2019, SOL Global Investments Corp. (CSE: SOL) (OTCQB: SOLCF) (Frankfurt: 9SB) announced that its portfolio company, Heavenly Rx. Ltd., had closed on its US$30.06 million investment in Blühen Botanicals LLC, an industry-leading hemp and hemp-derived CBD biomass farming, processing, extraction and retail company headquartered in Knoxville, Tennessee.
SOL Global is an international investment company with a focus on, but not limited to, cannabis and cannabis-related companies in legal US states, the hemp and CBD marketplaces and the emerging European cannabis and hemp marketplaces. Its strategic investments and partnerships across cultivation, distribution and retail complement the company’s R&D program with the University of Miami. It is this comprehensive approach that is positioning SOL Global as a future frontrunner in the United States’ medical cannabis industry.
Gowling WLG advised SOL Global in this acquisition with a team that included Peter Simeon and Josh Almario.
NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.